Protheragen's adeno-associated virus (AAV) vector platform not only simplifies the development process of AAV vectors, but also takes its functionality to a new level, breaking through the barriers of animal-to-human transformation. Through our exclusive AAV platform, we proudly demonstrate our firm commitment to pioneering innovation in the field of gene therapy and vector delivery systems, and we are able to use our AAV vector platform to provide you with one-stop therapy development services for various diseases.
Learn MoreOur triad of AAV technology platforms streamlines the development of AAV vectors and amplifies their capabilities. Through our exclusive AAV platform, we showcase our unwavering dedication to innovation.
A new type of tissue-targeted AAV breaks through the barriers of animal-to-human transformation.
Solve the current problems of difficulty in amplification, high impurities and high cost of the three-plasmid system.
Double AAV connection to express genes that exceed the AAV packaging capacity.
Leveraging our advanced AAV vector platform, we assist global pharmaceutical companies in developing innovative drugs and therapies for a variety of diseases, especially ophthalmic diseases.
Learn MoreUtilizing our advanced AAV vector platform, we are committed to delivering seamless, end-to-end services for drug and therapy development. This approach not only accelerates development timelines but also enhances the efficiency and effectiveness of bringing innovative therapeutics to market.
Our AAVLinkTM platform is at the forefront of adeno-associated viral (AAV) vector development, leveraging our extensive expertise and state-of-the-art technologies to drive innovation in gene therapy.
